Vivus Inc. (NASDAQ: VVUS) is up 9.55% to $6.77 in pre-market trading following an announcement that the company’s experimental weight loss drug, Qnexa, helped overweight people lose an average of 11.4% of their body weight after two years in a clinical trial for the drug. Vivus has already traded 460,503 shares, which is a significant number for pre-market trading, compared with their daily average of 5,387,870. This move also comes during a 52-week range of $4.69 to $13.68.
Vivus is an American biopharma company. They currently offer MUSE, a treatment for erectile disfunction. The FDA is scheduled to make a decision on Qnexa’s application by October 28, 2010.
-Michael B. Sauter